Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery
CompletedPhase 1, Phase 2NCT02462681
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study aims to investigate the safety and the analgesic efficacy of adding Ketamine to bupivacaine 0.25% in thoracic PVB in patients undergoing modified radical mastectomy.
Study details
- Official title
- Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery
- Conditions
- Interventions
- Drug: paravertebral block
- Sponsor
- Assiut University
- Start date
- 2015-05
- Primary completion
- 2016-12
- Sex
- Female
- Age range
- from 25 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * all patients scheduled for elective modified radical mastectomy with axillary dissection will be enrolled in the study Exclusion Criteria: * patients with a known allergy to the study drugs * patients with bleeding diathesis * patients with infection at the site of injection * patients with central neuropathy * patients with liver impairment * patients with renal impairment * drugs or alcohol abusers * patients with psychiatric illnesses
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02462681